Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Internal Medicine



  • Resmetirom Tablets (Rezdiffra)

    The U.S. Food and Drug Administration has approved the first drug and first-in-class for the treatment of metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis). Resmetirom is a selective thyroid hormone receptor-beta partial agonist and was granted an accelerated approval. It is distributed by Madrigal Pharmaceuticals, Inc. as Rezdiffra.

  • Quality, not Quantity: Plant-Based Carbs Might Result in Less Weight Gain

    This long-term prospective study found that adults on low-carbohydrate diets rich in plant-based and whole grain sources of protein and fat experienced significantly less weight gain than those on other types of low-carbohydrate diets.

  • Food as Medicine? Follow the Evidence

    In this randomized, controlled study of more than 400 individuals with uncontrolled type 2 diabetes and food insecurity, an intensive intervention offering healthy groceries and educational efforts failed to significantly affect glycemic control but resulted in heightened engagement with preventive healthcare services in the intervention group compared to the control.

  • Can Bariatric Surgery Control Blood Pressure Long-Term?

    A randomized trial comparing bariatric surgery to medical therapy in hypertensive obese patients has shown that bariatric surgery effectively lowers blood pressure over five years of follow-up.

  • Doxycycline Reduces the Risk of C. difficile Infection in Patients Treated for CAP

    In a retrospective study from the VA, doxycycline was associated with a lower risk of C. difficile infection compared to azithromycin in hospitalized patients with community-acquired pneumonia.

  • What Are Those T Waves?

    The patient whose ECG appears in the figure presented to an ambulatory care clinic for chest pain. Is the patient likely to have hyperkalemia?

  • Iloprost Injection (Aurlumyn)

    The U.S. Food and Drug Administration has approved iloprost for the treatment of severe frostbite to reduce the risk of amputation of fingers or toes. Iloprost, a synthetic analog of prostaglandin, initially was approved in 2004 for the treatment of pulmonary arterial hypertension. For that indication, it was given a priority review, accelerated approval, breakthrough therapy, and orphan drug designations. Iloprost for the frostbite indication is distributed by Eicos Sciences as Aurlumyn.

  • Empowered Relief vs. CBT vs. Health Education for Low Back Pain

    This randomized clinical trial involving adults with chronic low back pain demonstrates that a single session of a pain management class, when compared to a full course of cognitive behavioral therapy, yields noninferior (clinically on par) outcomes in pain catastrophizing and several other measures at the three-month follow-up.

  • Rates of Ad Hoc PCI Higher for Multivessel and Left Main Diseases

    In this retrospective analysis of patients from the New York state percutaneous coronary intervention (PCI) and coronary artery bypass grafting databases, ad hoc PCI was performed frequently among patients with left main and multivessel disease. Also, variability in ad hoc PCI use among hospitals and physicians for these populations was high.

  • How Safe Is Cannabis for the Heart?

    A nationwide Danish study of new prescriptions for medical cannabis for chronic pain compared to control patients has found that the 180-day incidence of atrial fibrillation/flutter is two-fold higher, but the absolute number of arrhythmias is small.